Regeneron stock reviews a week of drug news ahead of results
Published on 10/17/2026 at 11:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWeekly developments and next session
- Regeneron announced a positive European regulatory opinion for Libtayo on October 16, 2026.
- Regeneron reported 84-week Pasatru results on October 12, 2026.
- The next Xetra session is scheduled for October 19, 2026.
Regeneron’s weekly review centers on clinical and regulatory developments dated October 12 and October 16, 2026. The company announced a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use supporting a less frequent Libtayo dosing schedule on October 16, according to Regeneron Pharmaceuticals.
Market context: Market report S&P 500.
The week in figures
The available Lang & Schwarz record shows EUR 710.20 at 11:00 p.m. CEST on October 16, 2026, with a previous close of EUR 710.00. The record predates the October 17 publication date, so no weekend percentage comparison is stated.
The next price is shown from the start of trading by the continuously updated real-time quote of Regeneron stock.
Chronology of the week
On October 12, Regeneron reported 84-week results from the Phase 3 OPTIMA trial of Pasatru in adults with fibrodysplasia ossificans progressiva. The company said no new heterotopic ossification lesions were observed between weeks 56 and 84 for Pasatru, compared with nine new lesions for placebo, based on computed tomography scans. The release was issued by Regeneron Pharmaceuticals.
On October 16, the CHMP recommendation supported Libtayo 700 mg every six weeks after an initial 12-week regimen of 350 mg every three weeks. It also supported a 15- to 30-minute infusion option for the 350 mg dose after a well-tolerated first infusion over 30 minutes, according to Regeneron Pharmaceuticals.
Dates of the coming week
The next Xetra session is October 19, 2026. Regeneron has also scheduled publication of its third-quarter 2026 financial and operating results for October 30, 2026, before U.S. financial markets open, according to the company’s investor-relations release.
